Target enrichment through selective sequencing

KeyGene reference: P232

Invention

The invented methodology is a combination of TarSeq and subsequent selective sequencing, which results in a highly effective method for target sequence enrichment. TarSeq is a CRISPR-based technology selectively isolating and targeting regions of interest and protecting them from exonuclease treatment, thereby allowing for PCR-free enrichment. Subsequently applying selective nanopore sequencing makes sure an optimal enrichment of target sequences is obtained.

Benefits

The technology is highly flexible with regard to target sequence length (e.g. 1-20 Kb) as well as the number of targets to be enriched. Moreover, the technology is PCR-free, allowing for comprehensive variation detection of single nucleotide polymorphisms (SNPs), structural variations (SVs) and base modification (e.g. C methylation). Moreover, it is not biased by preferential amplification of for instance specific alleles.

Vision

In research and fields like crop breeding, there is a high demand for a technology that can enrich important genomic loci of samples to be selectively sequenced in a cost-effective way without PCR bias. KeyGene’s targeted sequencing technology is specifically linked to long-read sequencing and therefore highly instrumental in elucidating complex genomic structures, like copy number variation, larger insertions, and deletions, and inversions.

Patent

Click on the link for an overview of the patent family in the European Patent Register: WO2022/112316

Please note that the European Patent Register may not be extensive and/or accurate, for which KeyGene is not responsible. Please contact your patent expert for further information.

Would you like to explore the possibilities for obtaining a license for this technology? You can directly contact our licensing team by mail.

Would you like to know more about our technologies and licensing possibilities? Visit our webpage about Licensing KeyGene’s proprietary technologies.